Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243221 | 0.84 | CYP3A4 (0.46) | SIGMAR1CYP3A4IDO1APPSPHK2 | |
| SCHEMBL6510298 | 0.78 | CYP3A4 (0.50) | SIGMAR1CYP3A4IDO1APPCYP1A2 | |
| SCHEMBL2355588 | 0.78 | CYP3A4 (0.50) | SIGMAR1CYP3A4IDO1APPCYP1A2 | |
| SCHEMBL20631948 | 0.77 | ALDH1A1 (0.42) | SIGMAR1CYP3A4IDO1APPSPHK2 | |
| SCHEMBL3032451 | 0.77 | CYP3A4 (0.41) | SIGMAR1CYP3A4IDO1APPSPHK2 | |
| SCHEMBL1004906 | 0.75 | CA2 (0.50) | SIGMAR1CYP3A4IDO1SPHK2SPHK1 | |
| SCHEMBL15352442 | 0.75 | SIGMAR1 (0.40) | SIGMAR1CYP3A4IDO1APPSPHK2 | |
| SCHEMBL7560719 | 0.75 | SIGMAR1 (0.40) | SIGMAR1CYP3A4IDO1APPSPHK2 | |
| SCHEMBL14022427 | 0.75 | SIGMAR1 (0.40) | SIGMAR1CYP3A4IDO1APPSPHK2 | |
| SCHEMBL11663225 | 0.75 | SIGMAR1 (0.40) | SIGMAR1CYP3A4IDO1APPSPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6888022-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ATHENA NEUROSCIENCES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | SIGMAR1 4176/4885CYP3A4 4360/4885IDO1 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.